Drug Profile

Opaganib - RedHill Biopharma

Alternative Names: ABC-294640; YELIVA

Latest Information Update: 06 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apogee Biotechnology Corporation
Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma; University of Louisville
Class Adamantanes; Amides; Anti-inflammatories; Antifibrotics; Antihypoglycaemics; Antineoplastics; Antirheumatics; Antithrombotics; Antivirals; Chlorobenzenes; Obesity therapies; Pyridines; Radioprotectives; Small molecules
Mechanism of Action Sphingosine kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Neuroblastoma; Cholangiocarcinoma
New Molecular Entity Yes
Available For Licensing Yes - Cancer; Inflammation

Phase II/III COVID-19 pneumonia
Phase II Cholangiocarcinoma; Prostate cancer
Preclinical Ebola virus infections; Neuroblastoma; Obesity; Radiation injuries; Triple negative breast cancer; Type 2 diabetes mellitus; Viral haemorrhagic fevers
Suspended Liver cancer
No development reported Acute radiation syndrome; Cancer; COVID 2019 infections; Inflammatory bowel diseases; Influenza A virus infections; Osteoarthritis; Renal fibrosis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease; Solid tumours
Discontinued Multiple myeloma

28 Jul 2026 Preclinical trials in Viral haemorrhagic fevers in Israel (PO), prior to July 2026
28 Jul 2026 Adverse events data from phase II/III trial in COVID-19 pneumonia (Adjunctive treatment) released by RedHill Biopharma
28 Jul 2026 Pharmacodynamics data from phase I trial in Ebola virus infections released by RedHill Biopharma

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com